Literature DB >> 18647459

Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects.

R E Hasenbosch1, J W C Alffenaar, S A Koopmans, J G W Kosterink, T S van der Werf, R van Altena.   

Abstract

BACKGROUND: Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised. The mechanisms of action and predisposing factors have not yet been fully understood.
METHOD: We conducted a retrospective study (1992--2007) in an attempt to find predisposing factors for optical neuropathy.
RESULTS: Visual disturbance was reported in 1.3% of the 760 patients treated with EMB; of these, 0.8% were EMB-related. We present the six cases; four were clearly overdosed, but in two obese patients dosage was correctly calculated for total body weight (TBW).
CONCLUSION: Analysis of the case histories and previous reports suggest that optical neuropathy may at least partly be caused by EMB overdosing due to daily dosing based on TBW instead of dosing on lean body mass.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647459

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  Dosing ethambutol in obese patients.

Authors:  Jan-Willem Alffenaar; Tjip van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-09       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.

Authors:  Ronald G Hall; Mark A Swancutt; Claudia Meek; Richard D Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study.

Authors:  Francisco Beraldi-Magalhaes; Suzanne L Parker; Cristina Sanches; Leandro Sousa Garcia; Brenda Karoline Souza Carvalho; Mariana Millan Fachi; Marcus Vinicius de Liz; Roberto Pontarolo; Jeffrey Lipman; Marcelo Cordeiro-Santos; Jason A Roberts
Journal:  Antibiotics (Basel)       Date:  2021-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.